Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| GlaxoSmithKline | INDUSTRY |
| Sanofi | INDUSTRY |
| Merck Sharp & Dohme LLC | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
Since 2002, Whooping cough surveillance in pediatric private practice has been set up in France. The results of the first years, 2002-2006, have confirmed the effectiveness of the Pertussis whole-cell (Pw) vaccine and in particular the duration of protection of 9/10 years. After evaluating cases in children vaccinated with Pw vaccines, the study aims today to analyze cases in children vaccinated with Pertussis acellular (Pa) vaccines used since 2002/2003 and to assess, on an outpatient basis, the impact of new vaccine recommendations in France (in 2013, introduction of a 2 + 1 schedule - 8 weeks, 4 months and a 11-month recall - and a 6-year recall, and in 2014, update in the recommendations of exams to be prescribed based on the child's age and vaccination status).
The whooping cough surveillance objectives are :
In case of suspected pertussis, real-time PCR and / or culture and / or (rarely) serology is / are still prescribed to the patient and / or his entourage.
Selected Pediatricians from the ACTIV group and the AFPA working in an outpatient clinic, located in different places in France, are participating in this network since 2001. The clinical evolution and the results of the examinations are transcribed on a case report form. The data are collected, firstly, during the visit where the diagnosis of whooping cough is suspected and a biological assessment requested (patient's medical history, clinical data, vaccination status and dates, as well as the search for a contaminated/contaminator) and secondly during the follow-up visit (results of the biological check-up and diagnosis, antibiotics potentially prescribed, and supplement data of the entourage, except in case of diagnosis of pertussis not retained).
All evaluations made by the pediatricians are regularly reviewed during meetings, and final diagnoses used are:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| non interventional study | Other |
| Measure | Description | Time Frame |
|---|---|---|
| Duration of pertussis vaccines protection | Evaluate the duration of protection of the Ca vaccines | at inclusion |
| Measure | Description | Time Frame |
|---|---|---|
| Clinical characteristics of pertussis | Describe the clinical characteristics of a population vaccinated | at inclusion |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
children under 18 years with suspected pertussis diagnosis
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Corinne Levy, MD | Contact | 0033148850404 | corinne.levy@activ-france.fr | |
| Stéphane Béchet, MsC | Contact | 0033148850404 | stephane.bechet@activ-france.fr |
| Name | Affiliation | Role |
|---|---|---|
| Nicole Guiso | Institut Pasteur | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| ACTIV | Recruiting | Créteil | 94000 | France |
Not provided
| Label | URL |
|---|---|
| Whooping cough surveillance in France in pediatric private practice in 2006-2015 | View source |
| Pertussis surveillance in private pediatric practices, France, 2002-2006 | View source |
| Guidelines for diagnosis of whooping cough |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D014917 | Whooping Cough |
| ID | Term |
|---|---|
| D001885 | Bordetella Infections |
| D016905 | Gram-Negative Bacterial Infections |
| D001424 | Bacterial Infections |
| D001423 | Bacterial Infections and Mycoses |
Not provided
Not provided
Not provided
Not provided
Not provided
| View source |
| D007239 | Infections |
| D012141 | Respiratory Tract Infections |
| D012140 | Respiratory Tract Diseases |